A pathogenic proteolysis–resistant huntingtin isoform induced by an antisense oligonucleotide maintains huntingtin function
Authors:
- Hyeongju KimHKHyeongju Kim
- Sophie LenoirSLSophie Lenoir
- Angela HelfrichtAHAngela Helfricht
- Taeyang JungTJTaeyang Jung
- Zhana K. KarnevaZKZhana K. Karneva
- Yejin LeeYLYejin Lee
- Wouter BeumerWBWouter Beumer
- Herma AnthonijszHAHerma Anthonijsz
- Levi C.M. BuilLBLevi C.M. Buil
- Gerard J. PlatenburgGPGerard J. Platenburg
Open Access
- 8 September 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (17)
Abstract
Huntington’s disease (HD) is a late-onset neurological disorder for which therapeutics are not available. Its key pathological mechanism involves the proteolysis of polyglutamine-expanded (polyQ-expanded) mutant huntingtin (mHTT), which generates N-terminal fragments containing polyQ, a key contributor to HD pathogenesis. Interestingly, a naturally occurring spliced form of HTT mRNA with truncated exon 12 encodes an HTT (HTT Δ12 ) with a deletion near the caspase-6 cleavage site. In this study, we used a multidisciplinary approach to characterize the therapeutic potential of targeting HTT exon 12. We show that HTT Δ12 was resistant to caspase-6 cleavage in both cell-free and tissue lysate assays. However, HTT Δ12 retained overall biochemical and structural properties similar to those of wt-HTT. We generated mice in which HTT exon 12 was truncated and found that the canonical exon 12 was dispensable for the main physiological functions of HTT, including embryonic development and intracellular trafficking. Finally, we pharmacologically induced HTT Δ12 using the antisense oligonucleotide (ASO) QRX-704. QRX-704 showed predictable pharmacology and efficient biodistribution. In addition, it was stable for several months and inhibited pathogenic proteolysis. Furthermore, QRX-704 treatments resulted in a reduction of HTT aggregation and an increase in dendritic spine count. Thus, ASO-induced HTT exon 12 splice switching from HTT may provide an alternative therapeutic strategy for HD.Keywords
Funding Information
- Nation Research Foundation of Korea (2016K1A1A2912057)
- European Union Horizon 2020 (EUREKA Eurostars 2 grant E!)
This publication has 49 references indexed in Scilit:
- Huntingtin Acts Non Cell-Autonomously on Hippocampal Neurogenesis and Controls Anxiety-Related Behaviors in Adult MousePLOS ONE, 2013
- Transgenic Mouse Model Expressing the Caspase 6 Fragment of Mutant HuntingtinJournal of Neuroscience, 2012
- Onset and Progression of Behavioral and Molecular Phenotypes in a Novel Congenic R6/2 Line Exhibiting Intergenerational CAG Repeat StabilityPLOS ONE, 2011
- Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington diseaseJournal of Clinical Investigation, 2011
- Cleavage at the 586 Amino Acid Caspase-6 Site in Mutant huntingtin Influences Caspase-6 ActivationIn VivoJournal of Neuroscience, 2010
- pARIS-htt: an optimised expression platform to study huntingtin reveals functional domains required for vesicular traffickingMolecular Brain, 2010
- Huntingtin facilitates polycomb repressive complex 2Human Molecular Genetics, 2009
- Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's diseaseHuman Molecular Genetics, 2008
- Huntingtin facilitates dynein/dynactin-mediated vesicle transportProceedings of the National Academy of Sciences of the United States of America, 2007
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997